Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT01970046
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT01970033
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 302
- Registration Number
- NCT01970059
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Beijing Tongren hospital affiliated to Capital Medical University, Beijing, China
🇨🇳Gansu Provincial Hospital, Lanzhou, Gansu, China
Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT01969318
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
A Phase Ⅰa Study of Remimazolam Tosylate in Healthy Volunteers
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT01970072
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2013-10-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT01965496
- Locations
- 🇨🇳
People's Liberation Army General Hospital of Chengdu Military Region, Chengdu, China
A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2013-10-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT01965509
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT01937689
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT01830660
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT01829841
- Locations
- 🇨🇳
Cancer Institute and Hospital Chinese Academy of Medical Sciences, Beijing, China
© Copyright 2024. All Rights Reserved by MedPath